|
1
|
Chen D, Li Y, Yu Z, Li Y, Su Z, Ni L, Yang
S, Gui Y and Lai Y: Downregulated microRNA-510-5p acts as a tumor
suppressor in renal cell carcinoma. Mol Med Rep. 12:3061–3066.
2015.PubMed/NCBI
|
|
2
|
Yang T, Thakur A, Chen T, Yang L, Lei G,
Liang Y, Zhang S, Ren H and Chen M: MicroRNA-15a induces cell
apoptosis and inhibits metastasis by targeting BCL2L2 in non-small
cell lung cancer. Tumour Biol. 36:4357–4365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Su Z, Chen D, Zhang E, Li Y, Yu Z, Shi M,
Jiang Z, Ni L, Yang S, Gui Y, et al: MicroRNA-509-3p inhibits
cancer cell proliferation and migration by targeting the
mitogen-activated protein kinase kinase kinase 8 oncogene in renal
cell carcinoma. Mol Med Rep. 12:1535–1543. 2015.PubMed/NCBI
|
|
4
|
Komabayashi Y, Kishibe K, Nagato T, Ueda
S, Takahara M and Harabuchi Y: Downregulation of miR-15a due to
LMP1 promotes cell proliferation and predicts poor prognosis in
nasal NK/T-cell lymphoma. Am J Hematol. 89:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang BS, Liu Z, Xu WX and Sun SL:
Functional polymorphisms in microRNAs and susceptibility to liver
cancer: a meta-analysis and meta-regression, Genetics and molecular
research. GMR. 13:5426–5440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo S, Xu X, Tang Y, Zhang C, Li J, Ouyang
Y, Ju J, Bie P and Wang H: miR-15a inhibits cell proliferation and
epithelial to mesenchymal transition in pancreatic ductal
adenocarcinoma by down-regulating Bmi-1 expression. Cancer Lett.
344:40–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zitman-Gal T, Green J, Pasmanik-Chor M,
Golan E, Bernheim J and Benchetrit S: Vitamin D manipulates
miR-181c, miR-20b and miR-15a in human umbilical vein endothelial
cells exposed to a diabetic-like environment. Cardiovasc Diabetol.
13:82014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsushita R, Seki N, Chiyomaru T,
Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataki H, Tatarano S,
Itesako T, et al: Tumour-suppressive microRNA-144-5p directly
targets CCNE1/2 as potential prognostic markers in bladder cancer.
British journal of cancer. 2015. View Article : Google Scholar
|
|
9
|
Xiao G, Tang H, Wei W, Li J, Ji L and Ge
J: Aberrant expression of MicroRNA-15a and MicroRNA-16
synergistically associates with tumor progression and prognosis in
patients with colorectal cancer. Gastroenterol Res Pract.
2014:3645492014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rasmussen F: Metastatic renal cell cancer.
Cancer Imaging. 13:374–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Patel C, Ahmed A and Ellsworth P: Renal
cell carcinoma: A reappraisal. Urol Nurs. 32:182–190; quiz 191.
2012.PubMed/NCBI
|
|
12
|
Alt AL, Boorjian SA, Lohse CM, Costello
BA, Leibovich BC and Blute ML: Survival after complete surgical
resection of multiple metastases from renal cell carcinoma. Cancer.
117:2873–2882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bottoni A, Piccin D, Tagliati F, Luchin A,
Zatelli MC and Uberti EC degli: miR-15a and miR-16-1
down-regulation in pituitary adenomas. J Cell Physiol. 204:280–285.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang XJ, Ye H, Zeng CW, He B, Zhang H and
Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic
cancer. J Hematol Oncol. 3:462010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Humplikova L, Kollinerova S, Papajik T,
Pikalova Z, Holzerova M, Prochazka V, Divoka M, Modriansky M,
Indrak K and Jarosova M: Expression of miR-15a and miR-16-1 in
patients with chronic lymphocytic leukemia. Biomed Pap Med Fac Univ
Palacky Olomouc Czech Repub. 157:284–293. 2013.PubMed/NCBI
|
|
16
|
Renjie W and Haiqian L: MiR-132, miR-15a
and miR-16 synergistically inhibit pituitary tumor cell
proliferation, invasion and migration by targeting Sox5. Cancer
Lett. 356:568–578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bhattacharya R, Nicoloso M, Arvizo R, Wang
E, Cortez A, Rossi S, Calin GA and Mukherjee P: MiR-15a and MiR-16
control Bmi-1 expression in ovarian cancer. Cancer Res.
69:9090–9095. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Satzger I, Mattern A, Kuettler U,
Weinspach D, Voelker B, Kapp A and Gutzmer R: MicroRNA-15b
represents an independent prognostic parameter and is correlated
with tumor cell proliferation and apoptosis in malignant melanoma.
Int J Cancer. 126:2553–2562. 2010.PubMed/NCBI
|
|
20
|
Ofir M, Hacohen D and Ginsberg D: MiR-15
and miR-16 are direct transcriptional targets of E2F1 that limit
E2F-induced proliferation by targeting cyclin E. Mol Cancer Res.
9:440–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Musumeci M, Coppola V, Addario A, Patrizii
M, Maugeri-Saccà M, Memeo L, Colarossi C, Francescangeli F, Biffoni
M, Collura D, et al: Control of tumor and microenvironment
cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene.
30:4231–4242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bandi N, Zbinden S, Gugger M, Arnold M,
Kocher V, Hasan L, Kappeler A, Brunner T and Vassella E: miR-15a
and miR-16 are implicated in cell cycle regulation in a
Rb-dependent manner and are frequently deleted or down-regulated in
non-small cell lung cancer. Cancer Res. 69:5553–5559. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanlon K, Rudin CE and Harries LW:
Investigating the targets of MIR-15a and MIR-16-1 in patients with
chronic lymphocytic leukemia (CLL). PLoS One. 4:e71692009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xin C, Buhe B, Hongting L, Chuanmin Y,
Xiwei H, Hong Z, Lulu H, Qian D and Renjie W: MicroRNA-15a promotes
neuroblastoma migration by targeting reversion-inducing
cysteine-rich protein with Kazal motifs (RECK) and regulating
matrix metalloproteinase-9 expression. FEBS J. 280:855–866.
2013.PubMed/NCBI
|
|
25
|
Luo Q, Li X, Li J, Kong X, Zhang J, Chen
L, Huang Y and Fang L: MiR-15a is underexpressed and inhibits the
cell cycle by targeting CCNE1 in breast cancer. Int J Oncol.
43:1212–1218. 2013.PubMed/NCBI
|
|
26
|
Li P, Xie XB, Chen Q, Pang GL, Luo W, Tu
JC, Zheng F, Liu SM, Han L, Zhang JK, et al: MiRNA-15a mediates
cell cycle arrest and potentiates apoptosis in breast cancer cells
by targeting synuclein-γ. Asian Pac J Cancer Prev. 15:6949–6954.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tian X, Zhang J, Yan L, Dong JM and Guo Q:
MiRNA-15a inhibits proliferation, migration and invasion by
targeting TNFAIP1 in human osteosarcoma cells. Int J Clin Exp
Pathol. 8:6442–6449. 2015.PubMed/NCBI
|
|
28
|
Chen D, Li Y, Yu Z, Su Z, Yu W, Li Y, Yang
S, Gui Y, Ni L and Lai Y: Upregulated microRNA-16 as an oncogene in
renal cell carcinoma. Mol Med Rep. 12:1399–1404. 2015.PubMed/NCBI
|
|
29
|
Chen F, Hou SK, Fan HJ and Liu YF:
MiR-15a-16 represses Cripto and inhibits NSCLC cell progression.
Mol Cell Biochem. 391:11–19. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lan F, Yue X, Ren G, Li H, Ping L, Wang Y
and Xia T: miR-15a/16 enhances radiation sensitivity of non-small
cell lung cancer cells by targeting the TLR1/NF-κB signaling
pathway. Int J Radiat Oncol Biol Phys. 91:73–81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao SM, Xing CY, Chen CQ, Lin SS, Dong PH
and Yu FJ: miR-15a and miR-16-1 inhibit the proliferation of
leukemic cells by down-regulating WT1 protein level. J Exp Clin
Cancer Res. 30:1102011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai
LS, Zhang L and Hu Y: miR-15a and miR-16 affect the angiogenesis of
multiple myeloma by targeting VEGF. Carcinogenesis. 34:426–435.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
von Brandenstein M, Pandarakalam JJ, Kroon
L, Loeser H, Herden J, Braun G, Wendland K, Dienes HP, Engelmann U
and Fries JW: MicroRNA 15a, inversely correlated to PKCα, is a
potential marker to differentiate between benign and malignant
renal tumors in biopsy and urine samples. Am J Pathol.
180:1787–1797. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Groen FL, Timmer LM, Menezes RX,
Diosdado B, Hooijberg E, Meijer GA, Steenbergen RD and Carvalho B:
Oncogenic role of miR-15a-3p in 13q amplicon-driven colorectal
adenoma-to-carcinoma progression. PLoS One. 10:e01324952015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Spinetti G, Fortunato O, Caporali A,
Shantikumar S, Marchetti M, Meloni M, Descamps B, Floris I,
Sangalli E, Vono R, et al: MicroRNA-15a and microRNA-16 impair
human circulating proangiogenic cell functions and are increased in
the proangiogenic cells and serum of patients with critical limb
ischemia. Circ Res. 112:335–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng X, Li A, Zhao L, Zhou T, Shen Q, Cui
Q and Qin X: Key role of microRNA-15a in the KLF4 suppressions of
proliferation and angiogenesis in endothelial and vascular smooth
muscle cells. Biochem Biophys Res Commun. 437:625–631. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao X, Zhang R, Qu X, Zhao M, Zhang S, Wu
H, Jianyong L and Chen L: MiR-15a, miR-16-1 and miR-17-92 cluster
expression are linked to poor prognosis in multiple myeloma. Leuk
Res. 36:1505–1509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shinden Y, Akiyoshi S, Ueo H, Nambara S,
Saito T, Komatsu H, Ueda M, Hirata H, Sakimura S, Uchi R, et al:
Diminished expression of MiR-15a is an independent prognostic
marker for breast cancer cases. Anticancer Res. 35:123–127.
2015.PubMed/NCBI
|
